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Community Medicine, University Medicine Greifswald, Greifswald, GermanyA B S T R A C TObjectives: This study was performed to assess the economic effect
of interventions affecting transitions between dementia care settings
in Germany. Methods: A Markov-model that models the course of
dementia with respect to typical care setting transitions was derived.
Model data and parameters were retrieved by literature reviews. A
deterministic and probabilistic sensitivity analysis was conducted to
account for parameter uncertainty. Results: In the base case, the
expected present value of remaining lifetime costs is €25,326 for each
cohort member. As a function of effectiveness, pharmaceutical inter-
ventions may reduce the costs by 2% to 13% and psychosocial
interventions come with savings of 1% to 10%. A structural interven-
tion–promoting group living as a substitute for nursing home careee front matter Copyright & 2014, International S
r Inc.
1016/j.jval.2014.06.008
ke@rub.de.
ondence to: Sven Lueke, Faculty of Law and Busine
Friedrich-Löfﬂer-Straße 70, D-17489 Greifswald, Gincreases costs by 2% to 8%. Sensitivity analyses indicate high
variance and variability of results, as well as valuation of informal
care being a crucial parameter. Conclusions: There are economic
beneﬁts of delayed transitions to institutional settings, especially from
the viewpoint of statutory care insurances, but these do unlikely exceed
intervention costs. Thus, further intervention effects should be considered.
Ultimately, concentrating research on preventive and protective factors of
dementia could lead to an efﬁcient intervention from every perspective.
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Copyright & 2014, International Society for Pharmacoeconomics and
Outcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Dementia and its underlying diseases (e.g., Alzheimer’s disease),
epidemiology, and economic impact are well studied, but there
are still some unresolved issues. First, the biomedical causes and
effects of degenerative processes are not completely understood.
For example, though there are correlations between dementia
and mortality, there is currently no identiﬁable causal connection
[1]. Second, the cost of illness of dementia is well known but does
barely correlate with the progression of cognitive decline [2,3].
Thus, it is barely possible to predict the economic effects of
innovative interventions slowing down progression. Current
intervention concepts, nevertheless, focus on slowing down
cognitive decline.
Interestingly, a reliable cost predictor is the setting of the care
situation, whereby each setting is associated with certain types of
cost in varying amounts. In the case of a transition from home to
a nursing home, informal care is replaced by formal care, for
example. Only few studies have dealt with this issue [4,5].
Furthermore, a transition may have economic effects on different
payer perspectives.
The aim of this article was to analyze the economic effects of
interventions affecting transitions between care settings, namely,
from societal and payer perspectives. The analysis wasexempliﬁed on the basis of the care situation in Germany, a health
care system with three separate payer entities: statutory health
insurance (Gesetzliche Krankenversicherung), statutory care insur-
ance (Soziale Pﬂegeversicherung), and patients (households).Methods
The course of dementia depicts a continuous, vectored decline of
cognitive ability and other functions. For the purpose of this
analysis, a Markov-modeling study was conducted. The model
consists of six states: a state of healthy population (sHealthy), a
state of dead population (sDead), and four states for people with
dementia in different care settings. These care settings are living
at home with formal care (sHomeMinus), living at home with
formal and, in addition, informal care (sHomePlus), living in a
group living facility (sGroupLiving), and living in a nursing home
(sNursingHome). Several transitions between the states are pos-
sible, as depicted in Figure 1.
Starting from sHealthy, each population member is at risk to
develop dementia that is also diagnosed or to die (going to sDead)
per cycle. The state sHealthy comprises the initial population, that
is, the population without dementia, but at risk of developing
dementia. Therefore, no costs speciﬁc to dementia were associatedociety for Pharmacoeconomics and Outcomes Research (ISPOR).
ss Administration, Chair of Business Administration and Health
ermany.
Fig. 1 – Model structure and processes (bubble diagram).
V A L U E I N H E A L T H 1 7 ( 2 0 1 4 ) 6 7 9 – 6 8 5680with this state. Likewise, the state sDead, representing the dead
population of the model cohort, is not associated with any costs.
The population with newly diagnosed dementia will go to
sHomePlus and sHomeMinus, respectively. This means that a
proportion of people with newly diagnosed dementia lives in a
care setting in which formal care is provided and, in addition,
support from informal caregivers (family and friends) is available
(sHomePlus). For this reason, this state comprises formal care
costs (e.g., professional home care) and informal care costs (e.g.,
caregiver time for care and support). The other proportion of
people with newly diagnosed dementia lives in a care setting in
which informal support is not available (sHomeMinus). As a
consequence, only formal care costs are relevant.
With each modeling cycle, there are different transitions
between care settings possible, which were identiﬁed on the
basis of empirical evidence [6,7]. Possible transitions occur from
sHomePlus and sHomeMinus to sGroupLiving, sNursingHome,
and sDead. The state sGroupLiving represents a small institution-
based facility that provides dementia-speciﬁc formal care and
accommodation in a familiar group (8–12 people). The state
sNursingHome represents an institution-based facility as well,
but here on a larger scale. Thus, both institution-based care
settings have speciﬁc formal care costs and also differing cost of
living in contrast to home-based care settings (sHomePlus and
sHomeMinus). A transition from sHomePlus to sGroupLiving or
sNursingHome illustrates the collapse of informal care at home.
Common reasons for this collapse are caregivers’ illness or
burden due to severe deterioration in patients’ cognitive andTable 1 – Transition rates.
Parameter Description
tpDeath Transition rate from all states to sDeath
tpDiag1 Transition rate from sHealthy to sHomePlus
tpDiag2 Transition rate from sHealthy to sHomeMinu
tpHomePlus Transition rate from sGroupLiving to sHomeP
tpHomeMinus Transition rate from sGroupLiving to sHomeM
tpGroupLiving1 Transition rate from sHomePlus to sGroupLiv
tpGroupLiving2 Transition rate from sHomeMinus to sGroupL
tpGroupLiving3 Transition rate from sNursingHome to sGrou
tpNursingHome1 Transition rate from sHomePlus to sNursingH
tpNursingHome2 Transition rate from sHomeMinus to sNursin
tpNursingHome3 Transition rate from sGroupLiving to sNursin
sDead, a state of dead population; sHealthy, a state of healthy population
home with formal and informal care; sGroupLiving, living in a group livfunctional abilities. Consequently, a home-based care is not
feasible anymore. Likewise, transitions occur from sHomeMinus
but, because of the absence of informal support and restricted
independence, at an earlier point of time. There are several
transitions from sGroupLiving. A worsening health state may
necessitate a comprehensive care in a nursing home (transition
to sNursingHome). Also, returning home from sGroupLiving
(because of dissatisfaction, for example) is possible, because
cognitive and functional decline may not have reached an
advanced state yet. Because of its degenerative course, people
with dementia are likely to stay in sNursingHome. Nevertheless,
there are also transitions from sNursingHome to sGroupLiving
because some residents favor a more familiar care setting.
The model structure refers to the disease progression of
dementia by taking a multidimensional instead of a single-
dimensional decline (e.g., Mini-Mental State Examination scale)
into consideration. This multidimensional decline is marked by
declines in cognition, function (e.g., activities of daily living), and
behavior (e.g., agitation and wandering), expressing an overall grade
of dependency. In turn, the grade of dependency determines the
need for institutional care (nursing home) and the expected level of
caregiver burden and is a causal predictor for care costs [2,3].
The model states are associated with several parameters,
namely, transition rates to other states and speciﬁc costs. The
model parameters were retrieved by searching scientiﬁc data-
bases (PubMed, PsycINFO, Springerlink, Thieme) for reviews or
ﬁeld studies, respectively. Furthermore, relevant national scien-
tiﬁc reports were included, for example, on group living and care
situation of elderly and people with dementia in Germany.
Table 1 outlines the transition rates of the model, which were
standardized on 1 year.
The age-speciﬁc mortality rates are based on mortality tables
of the Federal Bureau of Statistics (Statistisches Bundesamt) [8].
The product of the age-speciﬁc incidence rates and a constant
diagnostic detection rate (81.5%) equals tpDiag 1 and tpDiag 2,
that is, the transition probabilities from sHealthy to sHomePlus
and sHomeMinus for each cycle [9,10].
Table 2 displays the cost parameters of the model, which refer
to the Markov states sHomePlus, sHomeMinus, sGroupLiving, and
sNursingHome.
The cost of living in sHomePlus and sHomeMinus was assumed
to be identical because most of the informal caregiving is provided
by people who often do not live in the same home (e.g., daughter-
in-law) [6]. Also, the cost of formal care was assumed to be the
same in sHomePlus and sHomeMinus. The assumption is that the
need for professional care does not depend on the existence of
informal support because informal care is rather seen as an add-onValue Reference
Age-speciﬁc Statistisches Bundesamt [8]
Age-speciﬁc Bickel [9], Boustani et al. [10]
s Age-speciﬁc Bickel [9], Boustani et al. [10]
lus 0.083 Wolf-Ostermann [7]
inus 0.083 Wolf-Ostermann [7]
ing 0.01 Assumption: 1% per year
iving 0.01 Assumption: 1% per year
pLiving 0.045 Wolf-Ostermann [7]
ome 0.181 Luppa et al. [11]
gHome 0.267 Ebly et al. [12]
gHome 0.093 Wolf-Ostermann [7]
; sHomeMinus, living at home with formal care; sHomePlus, living at
ing facility; sNursingHome, living in a nursing home.
Table 2 – Costs.
Parameter Description Payers* Value Reference
cDiagnostics Cost of dementia diagnostics GKV:100% €164 (per
case)
Lueke [13]
cFormCare Formal care in sHomePlus and
sHomeMinus
SPV:100% €5,620 (per
year)
Leicht et al. [14]
cInfCare Informal care in sHomePlus SPV: 29% €14,419 (per
year)
Leicht et al. [14], Schwarzkopf et al. [15]
Patient:71%
cHomeLiving Cost of living in sHomePlus and
sHomeMinus
Patient:100% €9,685 (per
year)
Statistisches Bundesamt [16], Deutscher
Mieterbund [17]
cGroupLivingCare Formal care in sGroupLiving SPV: 25%
Patient:75% €36,000 (per
year)
Estimated on the basis of Kremer-Preiß
and Narten [18]
cGroupLivingLiving Cost of living in sGroupLiving Patient:100% €8,100 (per
year)
Kremer-Preiß and Narten [18]
cNursingHomeCare Formal care in sNursingHome SPV: 69% €21,520 (per
year)
Statistisches Bundesamt [19]
Patient:31%
cNursingHomeLiving Cost of living in sNursingHome Patient:100% €11,644 (per
year)
Statistisches Bundesamt [19], Augurzky
et al. [20]
GKV, Gesetzliche Krankenversicherung; sHomeMinus, living at home with formal care; sHomePlus, living at home with formal and informal
care; sGroupLiving, living in a group living facility; sNursingHome, living in a nursing home; SPV, Soziale Pﬂegeversicherung.
 Expected percentage of costs for a certain payer.
V A L U E I N H E A L T H 1 7 ( 2 0 1 4 ) 6 7 9 – 6 8 5 681service to formal care, thus sustaining home care for an extended
period of time. Therefore, a lack of informal support assumingly
results in a premature transition to an institutional setting.
The informal care costs were calculated by applying the
replacement cost approach [21]. For that, each hour of informal
care (on average 12.34 h/wk [14]) was valued with €22.47 (average
cost per hour of a professional care service [15]). In case of
relevance, an expected percentage of costs was calculated for
each payer by the use of legal maximum payment-offsets for
payer institutions (SPV) [22]. The cost of living (cHomeLiving,
cGroupLivingLiving, cNursingHomeLiving) was balanced to cLiv-
ing; that is, this cost type reﬂects additional or saved expenses on
living due to nursing home admissions.
A cohort simulation was performed, whereby one modeling
cycle represents 1 year. The initial population consisted of
100,000 healthy people aged 65 years. Thirty-ﬁve years were
modeled, leaving the survivals at an age of 100 years. All costs
were discounted at 5% per annum.
The effect of three hypothetic interventions was analyzed,
namely, a pharmaceutical intervention, a psychosocial intervention,
and a structural intervention. The pharmaceutical intervention
slows down cognitive decline in the course of dementia and
affects all people with dementia in the model (model states:
sHomePlus, sHomeMinus, sGroupLiving, and sNursingHome).
The intervention affects the transition rates from sHomePlus
and sHomePlus to sGroupLiving (tpGroupLiving 1 and 2) and
sNursingHome (tpNursingHome 1 and 2) because the slowdown
of disease progression results in a delayed institution-based care.
As a reference point for the cost of this hypothetic intervention,
the costs of current drugs were applied, which are approximately
€1548 per person and year [23]. The psychosocial intervention
enhances the coping strategies of informal caregivers (affected
state: sHomePlus) and so the need for institution-based care is
delayed. Consequently, the transition rates from sHomePlus to
sGroupLiving (tpGroupLiving 1) and sNursingHome (tpNursing-
Home 1) are modiﬁed. The structural intervention promotes
group living as a substitute for nursing home care. As a conse-
quence, there are more transitions from sHomePlus and sHome-
Minus to sGroupLiving than to sNursingHome.
The economic effects of these interventions were each com-
pared in a scenario analysis to a base case in which all transitionrates are on default. In addition, the results of the interventions
were compared with a hypothetical primary prevention in
dementia. Primary prevention is deﬁned as avoiding new occur-
rences of dementia cases by targeting the healthy population in
sHealthy, thus successively reducing incidence rates of dementia
by a certain percentage. The age-speciﬁc incidence rates of
dementia are displayed in Appendix 1 in Supplemental Materials
found at http://dx.doi.org/10.1016/j.jval.2014.06.008. All interven-
tions (pharmaceutical, psychosocial, structural, and primary
preventive) have a constant effect on the targeted population
with each modeling cycle.
To estimate the robustness of results, a deterministic sensi-
tivity analysis was performed to examine results’ dependence on
single parameters. Also, a probabilistic sensitivity analysis that
analyzes parameter uncertainty from a multivariate viewpoint
was performed. Because there are only few data on variance and
variability of parameters for the probabilistic analysis, theoretical
parameter distributions such as triangular and gamma distribu-
tion were chosen. The assumptions and estimations made are
displayed in Table 3.
A triangle distribution was applied in case only very limited
data were available for the distribution of costs and transition
probabilities. A gamma distribution was applied for some of the
data with evidence on the shape of the distribution.
Because modeling means to reduce complexity, several
assumptions have to be made. First, the model structure ignores
alternative risks of institutionalization and does not allow tran-
sitions to depend on earlier transitions as is characteristic for
Markov models. Second, dementia is assumed to have no speciﬁc
impact on mortality. And third, the different care settings are not
supposed to inﬂuence quality of life, medical costs, or mortality.Results
The simulation of the base case shows the model results in the
default, that is, without any intervention. After half of the model
runtime, roughly half of the initial population is still healthy, while
10% have dementia and approximately 40% are dead. The
remaining-lifetime risk for dementia is 33%. The expected present
value of remaining-lifetime costs is €25,326 per cohort member.
Table 3 – Assumptions for the probabilistic sensitivity analysis.
Parameter Statistical distribution Minimum value Maximum value Estimation/reference
tpHomePlus Triangular 0.0664 0.0996 20%
tpHomeMinus Triangular 0.0664 0.0996 20%
tpGroupLiving1 Triangular 0.008 0.012 20%
tpGroupLiving2 Triangular 0.008 0.012 20%
tpGroupLiving3 Triangular 0.036 0.054 20%
tpNursingHome1 Triangular 0.053 0.309 Luppa et al. [11]
tpNursingHome2 Triangular 0.2136 0.3204 20%
tpNursingHome3 Triangular 0.0837 0.1023 20%
cGroupLivingCare Triangular 32,400 39,600 10%
Alpha Lambda
Informal care time per week Gamma 0.3279 0.0266 Leicht et al. [14]
cDiagnostics Gamma 27.0429 0.1651 Lueke [13]
cFormCare Gamma 0.1498 2.6657 Leicht et al. [14]
cDiagnostics, cost of dementia diagnostics; cFormCare, cost of formal care in sHomePlus and sHomeMinus; cGroupLivingCare, cost of formal
care in sGroupLiving; tpGroupLiving1, transition rate from sHomePlus to sGroupLiving; tpGroupLiving2, transition rate from sHomeMinus to
sGroupLiving; tpGroupLiving3, transition rate from sNursing Home to sGroupLiving; tpHomeMinus, transition rate from sGroupLiving to
sHomeMinus; tpHomePlus, transition rate from sGroupLiving to sHomePlus; tpNursingHome1, transition rate from sHomePlus to sNursin-
gHome; tpNursingHome2, transition rate from sHomeMinus to sNursing Home; tpNursingHome3, transition rate from sGroupLiving to
sNursingHome.
V A L U E I N H E A L T H 1 7 ( 2 0 1 4 ) 6 7 9 – 6 8 5682A closer look at these costs of care reveals that especially
institutional care sums up to more than half of the costs
(cGroupLivingCare, €2,508; cNursingHomeCare, €11,526). The cost
for informal care (cInfCare) is likewise a relevant cost type
summing up to €7,266, whereas the cost of formal care at home
(cFormCare) is €3,055. A comparably minor cost type is cDiag-
nostics with €32. Considering the cost of living, €939 extra
expenses are necessary due to nursing home admissions.
In case of decreasing the age-speciﬁc incidence rate of
dementia (primary prevention) in certain effectiveness intervals
without intervention costs, the expected present value of
remaining-lifetime costs of dementia care is €19,809 (25% effec-
tiveness), €13,806 (50%), €7,237 (75%), and €0 (100%), respectively.
In the ﬁrst intervention scenario, the progression of dementia
is slowed down by means of a pharmaceutical intervention
leading to a decrease in the institutionalization rates of institu-
tional care facilities (group living, nursing home). Table 4 com-
pares the results with the base case depending on effectiveness.
The intervention gradually reduces expenses for institutional
care costs, while formal and informal care costs are increased on
a remaining-lifetime scope. Both the statutory care insurance and
patients beneﬁt from saved costs because of delayed or averted
institutionalizations. However, the largest share accounts for the
statutory care insurance with approximately 85% of savings.
Taking the costs of the current drug treatments into account
(expected costs, €1778 per person), an effectiveness of approx-
imately 75% is needed for a breakeven. This means that the
transition probability to institution-based care has to be
decreased by 75% to reach savings equal to the intervention
costs. In case only people with dementia at home receive
respective medications, an effectiveness of 50% is needed.
In a second intervention scenario, a psychosocial intervention
enhancing caregiver’s coping strategies is introduced. The
enhancement leads on to the ability to care for a spouse with
dementia or a relative for an extended period of time. Accord-
ingly, this intervention affects the population in sHomePlus only.
In this scenario, the expected total costs are reduced by €349 (25%
effectiveness), €920 (50% effectiveness), €1483 (75% effectiveness),
and €2276 (100% effectiveness). In correspondence with a phar-
maceutical intervention, costs are also saved because of delayed
or averted institutionalizations. Because of its restricted effectrange, the savings are slightly lower. Solely the statutory care
insurance beneﬁts from the intervention, whereas the patients’
budget is neither debited nor credited.
The third intervention scenario is an increasing share of
institutionalizations in favor of group living instead of nursing
home care; that is, the structure of institutionalized care for
people with dementia is changed. In this scenario, the total costs
are increased by €389 (25% effectiveness), €822 (50% effective-
ness), €1305 (75% effectiveness) and €1845 (100% effectiveness).
The results show that promoting group living leads on to a higher
expected present value of remaining-lifetime costs in dementia
care. The reason is that care costs in group living facilities exceed
nursing home care costs by far. The cost of nursing home care is
reduced by €1797 to €8416, whereas the cost of group living is
increased by €2101 to €9876. Yet, there are savings related to the
cost of living (e.g., €539 at 50% effectiveness). Despite this fact, the
statutory care insurance beneﬁts from this intervention, starting
from €517 to €2418. Patients, however, are debited from €906 up
to €4.263.
As a matter of course, all results depend on parameter
validity. Figure 2 shows the responsiveness of the base-case
results to several parameters.
The discount rate (base case, 5%) and valuation of informal
care time (base case, €22.47/h) are both crucial parameters with
respect to modeling results. However, the discount rate is
relevant in terms of absolute effects only, whereas using varying
valuation methods for informal care time affects the relative
advantageousness of interventions.
The probabilistic sensitivity analysis provides information on
the results’ variance, within the limits of assumptions made. The
expected present value of remaining-lifetime costs is €24,641
with a standard deviation of €13,889. The conﬁdence interval
(95%) lies between the boundaries €14,320 and €63,396.Discussion
The analyses show that there are certain economic effects when
transition rates in dementia care are affected. This fact is pivotal
for public health issues. The planning and implementation of
innovative care strategies requires interventions to be effective
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V A L U E I N H E A L T H 1 7 ( 2 0 1 4 ) 6 7 9 – 6 8 5 683and efﬁcient as well. Affecting transition rates in dementia care is
an important lever to avoid wasting health care resources.
However, interventions need a presumably high effectiveness
to yield a suitable cost-efﬁciency. There are some pharmaceutical
drugs available that claim to slow down cognitive decline in
dementia, for example, acetyl cholinesterase inhibitors and N-
Methyl-D-aspartate-antagonists. Current medications have not
yielded proven major effects on slowing down cognitive decline
but have shown some limited impact on the course of dementia
[24]. Taking current medication prices into account, at least 50%
to 75% effectiveness is needed for a balanced result between
intervention costs and economic effects. Although a pharma-
ceutical intervention would be particularly beneﬁcial for the
statutory care insurance, the effectiveness needed presents a
major obstacle for cost-efﬁciency.
Because psychosocial interventions solely focus on caregivers
of informal care, effectiveness has to be even larger than in the
pharmaceutical intervention or intervention costs have to be very
low to reach cost-efﬁciency. Fostering group living is presumably
not associated with speciﬁc intervention costs, but at the
moment this is an even more expensive option compared with
nursing homes. Interestingly enough, German care policy tends
toward promoting group living as an alternative to nursing
homes.
Because Germany has various payer institutions in the health
care system, each transition affected also has effects on payer
budgets. The interventions described focus mainly on crediting
statutory care insurance, while patients’ expenses will just
slightly decrease or even increase. Can this result be applied to
other health care systems? A comparison in quantitative terms is
difﬁcult for various reasons, for example, differing ﬁnancing
systems, health services, and cost structures. So, the model’s
transition probabilities and costs assumingly vary among differ-
ent health care systems. However, the results’ qualitative state-
ment is assumingly valid for other health care systems:
interventions intending to avoid institutionalizations lead on to
a shift from formal care cost to informal care cost. From an
economic point of view, cash costs (formal care) are replaced by
noncash costs (informal care).
Comparisons to other economic models of dementia are
hardly possible. On the one hand, informal care costs are often
not considered (see Jones et al. [5]), so avoiding nursing home
admissions would lead to an even higher cost-effectiveness. On
the other hand, most studies still focus on using cognitive states
as a predictor for care cost, for example, Neumann et al. [4].
Interestingly, values of transition probabilities vary widely
between models, and even across the published literature. A
systematic review from Luppa et al. [11], which served as a basis
for the present analysis, identiﬁes annual transition probabilities
ranging between 4.5% and 44% from home-based to institution-
based care. In contrast, Spackman et al. [25] exempliﬁed by
means of a multinomial logistic model that the respective
transition probabilities may be even lower (1.2%–6.6% per year),
whereby only Alzheimer’s disease was included [25]. Although
the costs of dementia are well known, there are still knowledge
gaps regarding transition probabilities.
Limitations
There are some methodological limitations in the study that
correspond to the basic assumptions of the model. First, alter-
native risks of institutionalization were not considered, though
there might be other reasons of nursing home admissions. This
means that the model slightly overestimates the effect of transi-
tional interventions because a certain proportion is institution-
alized because of other reasons. Furthermore, in a Markov model,
transitions do not depend on earlier transitions. In reality, a
Fig. 2 – Deterministic sensitivity analysis.
V A L U E I N H E A L T H 1 7 ( 2 0 1 4 ) 6 7 9 – 6 8 5684transition between settings may inﬂuence the probability of
future transitions. For example, an undiagnosed dementia case
would have a higher chance of being detected in the future
because diseases’ progression would become more obvious.
Second, dementia was deﬁned as having no speciﬁc mortality
rate. There is knowledge about how people with dementia die [26]
and when they die [1], but there is a lack of causal connection
between dementia and death. A speciﬁc dementia mortality rate
would affect the modeling results in so far that less time is spent
in care settings. As a consequence, all costs would absolutely
decrease in the model runtime.
Third, quality of life, mortality, and medical costs were
assumed to be equal in all care settings and so these costs can
be neglected. The question whether dementia is associated with
restrictions in quality of life is arguable. Currently, there are no
unquestioned instruments measuring quality of life in dementia
and, even so, are ill suited for economic evaluation purposes [27].
One explanation is that there is no subjective decrease in quality
of life in dementia at all. From a medical point of view, this
concludes from the inability of patients with advanced dementia
to perceive their cognitive deterioration [28]. Another possible
explanation would be that current instruments are not sensitive
enough to measure quality of life in dementia. Nevertheless,
there are deﬁnitely studies needed to prove the effects of care
settings on quality of life, mortality, and medical costs.
Sensitivity analyses showed expectedly high variances and
standard deviations with discount rate and valuation of informal
care as crucial parameters. The valuation of informal care was
performed by applying the replacement cost approach. Anyhow,
there are still methodological challenges in assessing and valuing
informal care [21,29].Conclusions
Interventions affecting transitions between care settings are def-
initely related to economic effects. Within the limitations of the
modeling and simulation procedure, the results show that there
are some beneﬁts in modifying transition rates. Nevertheless,
interventions presumably need a high effectiveness to exceed
the particular intervention costs. Apart from this, the beneﬁts of
all interventions go most likely to the statutory care insurance.
Interestingly, group living is a favored and fostered care setting in
Germany, though the present analysis shows beneﬁts mainly from
an statutory care insurances’ perspective. From a public health
perspective, these insights help in planning effective and efﬁcient
interventions and may lead on to a more factual discussion on
cost-efﬁciency in innovative dementia care strategies.
Further on, additional research in the ﬁeld of care setting
transitions is needed, especially on transition rates, causes ofinstitutionalization, as well as costs. Also, there is a strong focus
on research on easing the burden of existing dementia cases, but
only few concentrate on preventive and protective factors for
future generations—a likewise effective and efﬁcient strategy in
the long term.
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